NASDAQ:GOVXW GeoVax Labs (GOVXW) Stock Price, News & Analysis → New way to “hijack” stocks (From DTI) (Ad) Free GOVXW Stock Alerts $0.04 0.00 (0.00%) (As of 06/14/2024 ET) Add Compare Share Share Today's Range$0.04▼$0.0450-Day Range$0.03▼$0.0652-Week Range$0.02▼$0.24VolumeN/AAverage Volume4,295 shsMarket CapitalizationN/AP/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock AnalysisChartCompetitorsFinancialsHeadlinesSEC FilingsShort InterestTrendsStock AnalysisChartCompetitorsFinancialsHeadlinesSEC FilingsShort InterestTrends Get GeoVax Labs alerts: Email Address Ad Crypto 101 Media$16T Crypto Plot From Elon MuskReports of a leaked meeting between Elon Musk and staff at X.com could send shockwaves through the crypto market. Musk revealed a "mind-blowing" plan to take over the global payment system. In his own words, the world's richest man said "you won't need a bank account." Prominent voices in crypto believe what comes next will mirror a crypto mass adoption similar to the one that triggered bitcoin's last bull run.Click here now to get your copy. About GeoVax Labs Stock (NASDAQ:GOVXW)GeoVax Labs, Inc., a clinical-stage biotechnology company, develops human vaccines and immunotherapies against infectious diseases and solid tumor cancers using modified vaccinia ankara virus-like particle vaccine platform. It is developing various preventive vaccines against (COVID-19), human immunodeficiency virus (HIV); Zika virus; malaria; and hemorrhagic fever viruses, such as Ebola, Sudan, Marburg, and Lassa, as well as therapeutic vaccines for HIV, chronic Hepatitis B infections, and solid tumor cancers. The company is developing GEO-CM04S1, a vaccine candidate that is in Phase 2 clinical trial for the treatment of preventive COVID-19; Gedeptin, a novel patented product/technology for the treatment of solid tumors, and Phase 1/2 clinical trial for the treatment of advanced head and neck squamous cell carcinoma; and GEO-CM02, a pan-coronavirus vaccine. In addition, it is developing GEO-ZM02, a vaccine candidate, which is in preclinical trial for the treatment of GEO-ZM02, a vaccine candidate, which is in preclinical trial for the treatment of Zika; GEO-MM02 treatment for malaria; other infectious disease vaccines for the treatment of fever viruses, such as Ebola, Sudan, and Marburg; GEO-LM01 for the treatment of Lassa fever. It has collaboration and partnership agreements with the National Institute of Allergy and Infectious Diseases of the National Institutes of Health; U.S. Department of Defense; Emory University; and the Burnet Institute. GeoVax Labs, Inc. was incorporated in 1988 and is headquartered in Smyrna, Georgia.Read More GOVXW Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart GOVXW Stock News HeadlinesMay 7, 2024 | finance.yahoo.comGeoVax to Report First Quarter 2024 Financial Results and Provide Corporate Update on May 14, 2024April 4, 2024 | finance.yahoo.comGeoVax Presents Data on GEO-CM04S1, a Next Generation Covid-19 VaccineMarch 28, 2024 | finance.yahoo.comGeoVax to Present Data on GEO-CM04S1, a Next Generation Covid-19 Vaccine, at the World Vaccine CongressFebruary 13, 2024 | finance.yahoo.comGeoVax Announces Multiple Patent Issuances and AllowancesFebruary 6, 2024 | finance.yahoo.comGeoVax Reports Positive Interim Data From Phase 2 Clinical Trial of GEO-CM04S1 as a Universal Covid-19 Vaccine BoosterJanuary 29, 2024 | finanznachrichten.deGeoVax, Inc.: GeoVax Announces 1-for-15 Reverse Stock Split to Regain Compliance with Nasdaq Minimum Bid RequirementJanuary 29, 2024 | markets.businessinsider.comEQS-News: GeoVax Announces 1-for-15 Reverse Stock Split to Regain Compliance with Nasdaq Minimum Bid RequirementJanuary 29, 2024 | finance.yahoo.comGeoVax Announces 1-for-15 Reverse Stock Split to Regain Compliance with Nasdaq Minimum Bid RequirementJanuary 4, 2024 | finance.yahoo.comGeoVax Announces Gedeptin® Patient Enrollment Closure for Phase 1/2 Clinical Trial Among Advanced Head and Neck Cancer PatientsDecember 27, 2023 | finance.yahoo.comGeoVax to Present at Biotech Showcase During J.P. Morgan Healthcare Week 2024December 19, 2023 | finanznachrichten.deGeoVax, Inc.: GeoVax Expands Rights Under NIH COVID-19 License to Include Mpox and SmallpoxDecember 19, 2023 | finance.yahoo.comGeoVax Expands Rights Under NIH COVID-19 License to Include Mpox and SmallpoxNovember 14, 2023 | finance.yahoo.comProgress on GeoVax’s Universal Coronavirus Vaccine Candidate, GEO-CM02, Presented at Vaccines Summit 2023November 8, 2023 | finance.yahoo.comGeoVax Reports Third Quarter 2023 Financial Results and Provides Business UpdateOctober 30, 2023 | finance.yahoo.comGeoVax Commences Site Expansion for Phase 2 Trial of Next-Generation COVID-19 VaccineOctober 25, 2023 | finance.yahoo.comGeoVax to Participate in Upcoming November Investor and Industry EventsOctober 9, 2023 | finance.yahoo.comGeoVax Receives Notice of Allowance for Marburg Vaccine PatentOctober 5, 2023 | finance.yahoo.comGeoVax Receives Notice of Allowance for HIV Vaccine PatentSeptember 26, 2023 | finance.yahoo.comGeoVax Secures Multi-Product License for ProBioGen's AGE1.CR.pIX® Suspension Cell Line to Bolster MVA-Based Vaccine DevelopmentSeptember 20, 2023 | finance.yahoo.comGeoVax Next-Generation COVID-19 Vaccine Data Presented at Keystone Symposia ConferenceAugust 29, 2023 | finance.yahoo.comGeoVax to Present at the Emerging Growth Conference on September 6, 2023August 10, 2023 | finance.yahoo.comGeoVax Announces First Patients Vaccinated in Phase 2 Clinical Trial of COVID-19 Vaccine Booster in Patients with Chronic Lymphocytic LeukemiaAugust 9, 2023 | finance.yahoo.comGeoVax Reports 2023 Second Quarter Financial Results and Provides Corporate UpdateJuly 24, 2023 | marketwatch.comGeoVax Labs Shares Rise 8% After Patent for Ebola VaccineJuly 11, 2023 | finance.yahoo.comGOVX - GeoVax Labs, Inc.See More Headlines Receive GOVXW Stock News and Ratings via Email Sign-up to receive the latest news and ratings for GeoVax Labs and its competitors with MarketBeat's FREE daily newsletter. Email Address Industry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Biotechnology Sub-IndustryN/A Current SymbolNASDAQ:GOVXW CUSIPN/A CIK832489 Webwww.geovax.com Phone16783847220FaxN/AEmployees17Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity RatioN/A Current RatioN/A Quick RatioN/A Sales & Book Value Annual Sales$81,526.00 Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book ValueN/A Price / BookN/AMiscellaneous Outstanding SharesN/AFree FloatN/AMarket CapN/A OptionableNot Optionable BetaN/A The 10 Best AI Stocks to Own in 2024Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.Get This Free Report Key ExecutivesMr. David Alan Dodd (Age 74)Chairman, President & CEO Comp: $384.2kDr. Mark J. Newman Ph.D. (Age 69)Chief Scientific Officer Comp: $291.5kDr. Kelly T. McKee Jr. (Age 73)M.D., M.P.H., Chief Medical Officer Comp: $361.03kDr. Harriet Latham Robinson Ph.D. (Age 86)Founder, Chief Scientific Officer Emeritus & Member of Scientific Advisory Board Mr. Mark W. Reynolds CPA (Age 62)CFO & Corporate Secretary Comp: $348.2kMr. Thomas O'BrienVice President of Quality Systems & ComplianceMr. Jeffrey WelchHead of Process Development & Manufacturing OperationsMr. John NilesHead of Commercial OperationsDr. John W. Sharkey Ph.D. (Age 68)Vice President of Business Development More ExecutivesKey Competitors180 Life SciencesNASDAQ:ATNFW60 Degrees PharmaceuticalsNASDAQ:SXTPWAlpha Tau MedicalNASDAQ:DRTSWApollomicsNASDAQ:APLMWArtelo BiosciencesNASDAQ:ARTLWView All Competitors GOVXW Stock Analysis - Frequently Asked Questions How have GOVXW shares performed in 2024? GeoVax Labs' stock was trading at $0.03 on January 1st, 2024. Since then, GOVXW stock has increased by 21.3% and is now trading at $0.0364. View the best growth stocks for 2024 here. How do I buy shares of GeoVax Labs? Shares of GOVXW stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:GOVXW) was last updated on 6/16/2024 by MarketBeat.com Staff From Our PartnersAI's Next Magnificent SevenThe Original Magnificent Seven Produced 16,894% Average Returns Over 20 Years.The Oxford Club | SponsoredTop 5 Tech Stocks to Buy for 2024The next evolution of technology is already upending industries worth $7 Trillion… It's already got the world'...Daily Market Alerts | SponsoredTop 5 AI Stocks to Buy for 2024The electric vehicle boom is accelerating – and fast.Market Moving Trends | SponsoredGold Set to EXPLODE!The perfect storm is brewing to drive gold's price through the roof! And our weakening dollars are causing ...Gold Safe Exchange | SponsoredHurry! Buy this stock before the Robinhood traders do!Robinhood traders have piled $78 billion into this market... Driving tiny tech stock gains of 3,000%, 8,942...Traders Agency | SponsoredWho are Nvidia’s Silent Partners?Nvidia recently became just the third $2 trillion company. But Nvidia can’t do everything by itself.Weiss Ratings | SponsoredMan who Predicted Trump 2016 Win: “Prepare for Election Meltdown”Former advisor to the CIA, the Pentagon and the White House Jim Rickards went on multiple TV news programs… ...Paradigm Press | SponsoredThe #1 Crypto That You Don’t Own… YetThere’s all kinds of “signals” to follow when investing in cryptos. But there’s one signal you should pay a...Crypto 101 Media | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding GeoVax Labs, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share GeoVax Labs With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.